References
- Lipsky PE, van der Heijde D, St Clair WF, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2003;343:1594–602.
- Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low-dose weekly metho-trexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552–63.
- Kavanaugh A, St. Clair EW, McCune WJ, et al. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol. 2004;27:841–50.
- Maini R, St. Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet. 1999;354:1932–9.
- Felson DT, Anderson JJ, Boews M, et al. American College of Rheumatology; preliminary definition of improvement in rheu-matoid arthritis. Arthritis Rheum. 1995;38:727–35.
- Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts; develop-ment and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8.
- Fries JF, Spits P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137–45.
- Chambers LW, Macdonald LA, Tugwell P, et al. The McMaster health index questionnaire as a measure of quality of life for patients with rheumatoid disease. J Rheumatol. 1982;9:780–4.
- Callahan LF, Pincus T. A clue from a self-report questionnaire to distinguish rheumatoid arthritis from noninflammatory diffuse musculoskeletal pain; the P-VAS: D-ADL ratio. Arthritis Rheum. 1990;33:1317–22.
- Lorish CD, Maisiak R. The face scale; a brief, nonverbal method for assessing patient mood. Arthritis Rheum. 1986;29:906–9.
- Ware JE, Sherbourne CD. The medical outcomes study, SF-36 item short form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–83.
- Steinbrocker 0, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA. 1949;140:659–62.
- Durez P, Nzeusseu Toukap A, Lauwerys BR, et al. A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment. Ann Rheum Dis. 2004;63:1069–74.
- Maini RN, Breedveld FC, Kalden JR, et al. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. Sustained improvement over two years in physical func-tion, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrex-ate. Arthritis Rheum. 2004;50:1051–65.
- Russell AS, Conner-Spady B, Mintz A, et al. The responsiveness of generic health status measures as assessed in patients with rheumatoid arthritis receiving infliximab. J Rheumatol. 2003;30:941–7.
- Birrell FN, Hassell AB, Jones PW, et al. How does the short form 36 health questionnaire (SF-36) in rheumatoid arthritis (RA) relate to RA outcome measures and SF-36 population values? A cross-sectional study. Clin Rheumatol. 2000;19:195–9.
- Jette AM. Functional status index; reliability of a chronic disease evaluation instrument. Arch Phys Med Rehabil. 1980;61:395–401.
- Meenan RF, Gertman PM, Mason JH. Measuring health status in arthritis; the arthritis impact measurement scales. Arthritis Rheum. 1980;23:146–52.
- Turner-Browker DM, Bayliss MS, Ware JE Jr, et al. Usefulness of the SF-8 health survey for comparing the impact of migraine and other conditions. Qual Life Res. 2003;12: 1003–12.